Literature DB >> 2995810

Sensitivity of the parathyroid hormone-1,25-dihydroxyvitamin D axis to variations in calcium intake in patients with primary hyperparathyroidism.

K L Insogna, M E Mitnick, A F Stewart, W J Burtis, L E Mallette, A E Broadus.   

Abstract

Previous studies have demonstrated a spectrum of parathyroid responsivity to alterations in the extracellular calcium concentration in patients with primary hyperparathyroidism, but studies employing physiologic amounts of calcium have not, to our knowledge, been reported. We studied 18 unselected patients with primary hyperparathyroidism at the lower (400 mg) and upper (1000 mg) limits of a normal dietary intake of calcium. The diet containing high-normal amounts of calcium induced only a slight increase in 24-hour calcium excretion (from 281 to 337 mg per day) yet was associated with significant reductions in fasting serum levels of immunoreactive parathyroid hormone (from 60 to 50 nleq per milliliter; P less than 0.001), nephrogenous cyclic AMP (from 3.52 to 2.63 nmol per deciliter of glomerular filtrate; P less than 0.001), and plasma levels of 1,25-dihydroxyvitamin D (from 74 to 58 pg per milliliter; P less than 0.001). A wide spectrum of responses was observed, with some patients appearing to have essentially autonomous parathyroid function and others having marked suppressibility (up to 50 per cent) of the parathyroid hormone-vitamin D axis. We conclude that parathyroid function may be suppressed by dietary calcium in some patients with primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995810     DOI: 10.1056/NEJM198510313131805

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  11 in total

1.  Weight loss and calcium intake influence calcium absorption in overweight postmenopausal women.

Authors:  Mariana Cifuentes; Claudia S Riedt; Robert E Brolin; M Paul Field; Robert M Sherrell; Sue A Shapses
Journal:  Am J Clin Nutr       Date:  2004-07       Impact factor: 7.045

2.  Effects of continuous glucocorticoid infusion on bone metabolism in the rat.

Authors:  C S King; E C Weir; C W Gundberg; J Fox; K L Insogna
Journal:  Calcif Tissue Int       Date:  1996-09       Impact factor: 4.333

3.  Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism.

Authors:  C Marcocci; M L Brandi; A Scillitani; S Corbetta; A Faggiano; L Gianotti; S Migliaccio; S Minisola
Journal:  J Endocrinol Invest       Date:  2015-03-28       Impact factor: 4.256

4.  Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades.

Authors:  Marcio L Griebeler; Ann E Kearns; Euijung Ryu; Prabin Thapa; Matthew A Hathcock; L Joseph Melton; Robert A Wermers
Journal:  J Clin Endocrinol Metab       Date:  2016-01-11       Impact factor: 5.958

5.  Hypertension, Antihypertensive Medications, and Risk of Incident Primary Hyperparathyroidism.

Authors:  Anand Vaidya; Gary C Curhan; Julie M Paik; Henry Kronenberg; Eric N Taylor
Journal:  J Clin Endocrinol Metab       Date:  2015-04-17       Impact factor: 5.958

6.  Secular trends in the incidence of primary hyperparathyroidism over five decades (1965-2010).

Authors:  Marcio L Griebeler; Ann E Kearns; Euijung Ryu; Matthew A Hathcock; L Joseph Melton; Robert A Wermers
Journal:  Bone       Date:  2014-12-11       Impact factor: 4.398

7.  Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo.

Authors:  E C Weir; G Terwilliger; L Sartori; K L Insogna
Journal:  Calcif Tissue Int       Date:  1992-07       Impact factor: 4.333

8.  Renal manifestations of primary hyperparathyroidism.

Authors:  Anurag Ranjan Lila; Vijaya Sarathi; Varsha Jagtap; Tushar Bandgar; Padma S Menon; Nalini Samir Shah
Journal:  Indian J Endocrinol Metab       Date:  2012-03

9.  Calcium intake and risk of primary hyperparathyroidism in women: prospective cohort study.

Authors:  Julie M Paik; Gary C Curhan; Eric N Taylor
Journal:  BMJ       Date:  2012-10-17

10.  Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism.

Authors:  Ranganathan R Rao; Harpal S Randeva; Sailesh Sankaranarayanan; Murthy Narashima; Matthias Möhlig; Hisham Mehanna; Martin O Weickert
Journal:  Endocr Connect       Date:  2012-06-08       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.